Barinthus Biotherapeutics
NEWS
After quietly filing plans for an initial public offering earlier this month, U.K.-based Vaccitech raised $110.5 million in its IPO.
At this time Vaccitech hasn’t priced its offering, although the report suggests they might sometime this month.
It’s March Madness in the life sciences industry, with money pouring in faster than LeBron James on a breakaway. Here’s where the big bucks went this week.
Infectious disease-focused Vaccitech, which partnered with AstraZeneca and Oxford University on the development and manufacturing of that company’s COVID-19 vaccine, raised $168 million in a Series B financing round.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
It was a busy week for clinical trial updates. Here’s a look.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
Biopharma and life sciences companies provide updates on their pipelines and business plans.
Vaccitech Ltd and the University of Oxford announce an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate currently being trialled by the University.
JOBS
IN THE PRESS